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Objectives: Within health economic models of metastatic cancer therapies assump-
tions on the relationship between progression-free survival (PFS) / time-to-progres-
sion (TTP) and overall survival (OS) are typically required; notably when OS data are 
immature or unavailable. A review was undertaken to identify the methods that have 
been used within health economic models regarding this relationship and to identify 
the rationale given for the approach taken, specifically in those situations where OS 
data were not available or immature. MethOds: All NICE technology appraisals in 
the advanced and/or metastatic cancer setting completed by December 2013 were 
reviewed. The review included all relevant appraisal documents publicly available on 
the NICE website containing information on the methods used and/or rationale for 
the approach taken to model the relationship between OS and PFS/TPP within the 
health economic model. This included the sponsor submission and updated analyses, 
the independent Assessment Report, and other reports/analyses in relation to the 
appraisal process. Results: In those instances where OS data were immature or not 
available, PFS/TTP was typically assumed to be a valid surrogate of OS. Justification 
for this assumption was inconsistently reported. In some health economic models 
a quantification of the assumed relationship was informed by published evidence 
and/or expert judgement. In some cases attempts were made to explore the potential 
impact of this relationship in sensitivity analysis. cOnclusiOns: The methods and/
or rationale given for the approach used to model the relationship between OS and 
PFS/TTP in health economic models has been inconsistently reported and justified. 
Whilst some health economic models attempted to quantify this relationship, further 
transparency is required. A consensus needs to emerge on the most appropriate 
approaches to be used within health economic models to quantify this relationship, 
specifically when OS data are not available or immature and to identify the circum-
stances when particular approaches may be most relevant.
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Objectives: Patient-level utility values for different stages of MBC and toxicities 
commonly associated with chemotherapy regimens are useful for health economic 
assessments. Three methods to estimate utilities exist when direct utility data are 
not available: utility ‘mapping’ from existing disease-specific scales, vignette studies 
that describe the health states; or derivation of preference-based measures from 
an existing condition-specific scale. This study compares utility estimates in MBC 
utilizing the above methods. MethOds: Based on data from a phase 3 clinical 
trial in MBC (N= 1102) utility mapping was conducted using a published regression 
algorithm to convert the EORTC QLQ-C30 questionnaire to the EQ-5D utility. Mean 
utility values were estimated for relevant health states: stable disease (SD), tumor 
response (TR), disease progression (DP) and common toxicities. Results were com-
pared to previously published values obtained for a vignette study conducted in 
one hundred members of the general public. Results: Observed MBC utilities were 
similar in mapping vs. vignette studies for SD: 0.697 vs. 0.715, and TR: 0.782 vs. 0.790. 
General public respondents in the vignette study assigned much lower utility to 
symptomatic DP (0.443) vs. imaging-based DP in mapping study (0.679); and disutil-
ity for toxicities: vomiting: 0.103 vs. 0.050; fatigue 0.115 vs. 0.029; febrile neutropenia 
0.150 vs. 0.012 (vignette vs. mapping respectively). Hand-foot syndrome, stomatitis 
and hair loss were not associated with disutility in the mapping study (potentially 
due to small sample size) while disutility of 0.116; 0.151; and 0.114 were reported 
by the vignette study. cOnclusiOns: Utilization of different methods to estimate 
utilities in MBC may lead to a wide range of estimated values with potentially sig-
nificant implications for health economic evaluation. Caution must be exercised 
when comparing utility values derived using different methods. It is preferable to 
collect such data from patients directly and use vignettes as a last resort.
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Objectives: To compare different COPD cost-effectiveness models with respect 
to structure and input parameters and to cross validate the models by running 
the same hypothetical treatment scenarios. MethOds: COPD modeling groups 
simulated four hypothetical interventions with their model and compared the 
results with a reference scenario of no intervention. The four interventions mod-
eled assumed: 1) 20% reduction in decline in lung function, 2) 25% reduction in 
exacerbation frequency, 3) 10% reduction in all-cause mortality and 4) all these 
effects combined. The interventions were simulated for a five-year and lifetime 
horizon with standardization, if possible, for sex, age, COPD severity, smoking status, 
exacerbation frequencies, mortality due to other causes, utilities, costs and dis-
count rates. Furthermore, uncertainty around the outcomes of intervention four was 
compared. Results: Seven out of nine contacted COPD modeling groups agreed to 
participate. Differences in 5-year QALY gains ranged from 0.00020 to 0.039 for inter-
vention one, 0.0089 to 0.075 for intervention two and 0.017 to 0.048 for intervention 
three. The difference in costs ranged from € 561 to € 912 for intervention one, € 739 
to € 1350 for intervention two and € 1140 to € 1618 for intervention three. The 5-year 
cost-effectiveness ratios (ICERs) for the most comprehensive intervention, interven-
tion four, was € 17,000/QALY for two models, € 25,000-€ 28,000/QALY for three models 
addition, the Dutch National Health Care Institute commented on usefulness for 
decision makers, while a separate group of 50 HE experts could comment during a 
workshop at ISPOR Montreal 2014. Results: 35 Validation techniques were identi-
fied and grouped into four categories: conceptual model validation, computerized 
model validation, data validation and operational validation. Around 30 HE experts 
commented in each of the first three Delphi rounds, resulting in a 15 item draft 
tool. The Dutch health care advisory institute suggested to add one more item. 
Participants from the ISPOR workshop delivered 19 filled-in questionnaires. A fourth 
round resulted in 17 responses. This led to a refined version containing 16 items, 
which is currently sent out for a final, fifth round. cOnclusiOns: When filled 
out by the modellers, AdVISHE (Assessment of the ValIdation Status of Health-
Economic decision models) supports model users in assessing the validation status 
of a model It will be useful as part of reimbursement dossiers, by providing system-
atic and transparent insight into the validation efforts performed and their results.
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Objectives: Traditional indirect treatment comparison methods assume the 
underlying survival profiles of treatments are similar (i.e. proportional hazards). This 
assumption is unlikely to hold for the comparison of ipilimumab and vemurafenib: 
Whereas vemurafenib exhibits improved short-term survival compared with ipili-
mumab, pooled study data for ipilimumab consistently show that patients achieve 
durable long-term survival. We present a method to compare across trials with dif-
fering survival profiles by accounting for follow-on treatments and different patient 
baseline characteristics. MethOds: Comparative survival estimates for ipilimumab 
and vemurafenib were produced using patient-level data from trial CA184-024 for 
ipilimumab and published survival curve fits from BRIM-3 (along with registry data) 
for vemurafenib. The BRIM-3 vemurafenib overall survival curve was adjusted to 
account for (a) the effect of second-line ipilimumab (via a tunnel-state methodol-
ogy) and (b) differences in patient baseline characteristics between BRIM-3 and 
CA184-024, by means of a model (Korn model), constructed to predict the outcomes 
for dacarbazine-treated patients. The resulting survival estimates were compared 
with naïve unadjusted survival curve fits, and estimates produced using a hazard 
ratio (from an indirect comparison) to the ipilimumab data. Results: Estimated 
survival for ipilimumab was 3.3 years (mean). Predicted survival for vemurafenib, 
using a naïve comparison, was 3.0 years (mean). Adjusting for second-line ipili-
mumab and different baseline characteristics resulted in an estimate of 2.8 years 
for vemurafenib. When a hazard ratio was applied to the ipilimumab data, which 
underlies the here strong assumption that the vemurafenib overall survival profile 
is similar to that of ipilimumab, predicted survival for vemurafenib increased to 4.2 
years.cOnclusiOns: Depending on the methodology used, the mean predicted 
survival for vemurafenib varied from 2.8 to 4.2 years. Alternative methods that 
incorporate the long-term survival profile of ipilimumab (naïve comparison or more 
sophisticated adjustment methodology) demonstrate a higher number of life years 
with ipilimumab versus vemurafenib. 
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Objectives: Alzheimer’s Disease destroys brain cells, causing problems with mem-
ory, thinking, and behavior severe enough to affect work, family and social relation-
ships, and, eventually, the most basic activities of daily living. Different treatment 
options have been introduced and evaluated from a health economic perspective. 
However, given the specific characteristics of the disease an evaluation of existing 
models is needed. MethOds: The following databases were searched systemati-
cally: PubMed, Health Technology Assessment Database, NHS Economic Evaluation 
Database, Cochrane Central Register of Controlled Trials, Cochrane Database of 
Systematic Reviews, DAHTA-database, PSYNDEX and PsycINFO. For the abstracts 
that met the pre-defined inclusion criteria, full text articles were obtained and 
evaluated for inclusion in the assessment. Results: After eliminating duplicates 
the search indicated yielded 1’219 articles of which another 940 were excluded based 
on the title selection. Finally 59 articles have been reviewed in full text after abstract 
review. Out of those articles 39 were deemed to be relevant based on the research 
question. The majority of models (48%) have been Markov models, other methods 
being used were various statistical analysis applications, micro-simulation, and 
discrete-event simulations. Limitations of existing models include the following: 
Focus on cognitive function as disease progression only; lack of inclusion of correla-
tion between disease progression and other factors (e.g. residential status); lack of 
complete structure of diagnosis and treatment of disease (e.g. including non-drug 
treatments). Based on the Drummond checklist for health economic models the 
quality of models proved generally to be high but the majority of those lack present-
ing a comprehensive pathway of the natural history of the disease. cOnclusiOns: 
Current models do not allow decision makers optimally characterizing the disease, 
to better assess the costs and benefits of a wide range of potential interventions. 
Potential new models need to take the disease characteristics and specifics more 
appropriate into account.
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